|
(1) Intestinal Organoid Models for APC LOH
|
5R21CA208638-02
|
$192,406
|
GIARDINA, CHARLES
|
UNIVERSITY OF CONNECTICUT STORRS
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
2U54CA163071-06
|
$1,427,230
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(2/2) CDU/UCLA Cancer Center Partnership to Eliminate Cancer Health Disparities
|
5U54CA143930-08
|
$704,474
|
FARIAS-EISNER, ROBIN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.
|
5R01CA208644-02
|
$377,438
|
CRITTENDEN, MARKA
|
PROVIDENCE PORTLAND MEDICAL CENTER
|
|
(PQ3) Cellular and Molecular Mechanisms Driving Myeloid Compartment Variation in Human Triple Negative Breast Cancer
|
1R01CA219880-01
|
$697,539
|
PALUCKA, ANNA KAROLINA
|
JACKSON LABORATORY
|
|
(PQ7)Multi-scale Analysis of Tumor Microenvironment Heterogeneity
|
1R01CA208735-01A1
|
$729,393
|
FELSHER, DEAN
|
STANFORD UNIVERSITY
|
|
(PQA-4) Organoid Omics To Detect And Defeat Ductal Pancreatic Cancer
|
5R01CA190092-04
|
$552,684
|
TUVESON, DAVID
|
COLD SPRING HARBOR LABORATORY
|
|
(PQA1)The Molecular Mechanisms Underlying Effects of Aspirin on Colorectal Cancer
|
5R01CA184820-04
|
$386,650
|
DUBOIS, RAYMOND
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
(PQB-4) Single cell analysis strategy for monitoring drug responses of tumors
|
5R01CA190122-04
|
$571,080
|
TIAN, QIANG
|
INSTITUTE FOR SYSTEMS BIOLOGY
|
|
(PQC-5) Zwitterionic NIR/Zr-89 Agents for Prostate Cancer Staging and Treatment
|
5R01CA185457-04
|
$640,378
|
FRANGIONI, JOHN
|
CURADEL, LLC
|
|
0021.0001 CG 425 METAVIVOR
|
261200800001E
|
$319,219,481
|
UNKNOWN, UNKNOWN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
0021.0001 CG 425 METAVIVOR
|
261200800001E
|
$319,219,481
|
UNKNOWN, UNKNOWN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
1/2 SDSU/UCSD Cancer Center Comprehensive Partnership
|
5U54CA132379-08
|
$1,258,708
|
MARTINEZ, MARIA
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
1/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
5P20CA192973-04
|
$191,836
|
MANNE, UPENDER
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
2/2 NCCU-LCCC Partnership in Cancer Research
|
5U54CA156733-08
|
$919,471
|
EARP, HENRY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
2/2 Ponce School of Medicine-Moffitt Cancer Center Partnership
|
2U54CA163068-06
|
$1,656,304
|
MUNOZ-ANTONIA, TERESITA
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
2/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
5P20CA192976-04
|
$144,556
|
MISHRA, MANOJ
|
ALABAMA STATE UNIVERSITY
|
|
2/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership
|
5U54CA118623-12
|
$407,680
|
TROY, ROBERTA
|
TUSKEGEE UNIVERSITY
|
|
A highly specific NIRF/PET probe for the detection of cancer and metastases
|
1R43CA210854-01A1
|
$224,958
|
Yang, Xinlin
|
IMOL RADIOPHARMACEUTICALS, LLC
|
|
A Microfluidics Approach to Investigate Tumor Cell Trafficking in Bone Marrow
|
1F32CA210540-01A1
|
$58,326
|
GLASER, DREW
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
|
A new imaging approach to radiotherapy planning for lung cancer
|
5R01CA193050-03
|
$535,497
|
RIZI, RAHIM
|
UNIVERSITY OF PENNSYLVANIA
|
|
A NOVEL EXTRACELLULAR AND INTRACELLULAR TREATMENT PARADIGM FOR ERADICATING CANCER
|
5F30CA189435-04
|
$49,044
|
SOM, AVIK
|
WASHINGTON UNIVERSITY
|
|
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
|
1R44CA217591-01
|
$621,000
|
KAHN, STUART
|
SYNTRIX BIOSYSTEMS, INC.
|
|
A Phase I Dose-escalation Study of Intraperitoneal CYN101 as Consolidation Immunotherapy in Women with Residual or Recurrent Ovarian Cancer Status after Chemotherapy
|
5R44CA206606-02
|
$1,004,186
|
WINRAM, SCOTT
|
CYNVEC, LLC
|
|
A simple assay system for rapid detection of circulating tumor cells
|
3R41CA183428-01A1S2
|
$50,000
|
HONG, BIN
|
TELOVISION, LLC
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-41S1
|
$125,000
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-41S2
|
$62,491
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
5P30CA016520-41
|
$7,810,244
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Academy of Behavioral Medicine Research Annual Conference
|
1R13CA216984-01
|
$7,580
|
MCCUBBIN, JAMES
|
CLEMSON UNIVERSITY
|
|
Adaptive resistance to HIF1a inhibition in hypoxia
|
5R01CA207377-02
|
$352,147
|
QIAN, ZHENG DAVID
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
An organotypic model recapitulating colon cancer microenvironment and metastasis
|
1U01CA214300-01A1
|
$560,162
|
HUANG, EMINA
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Analysis of Blood Borne Markers in Hormone Sensitive Metastatic Prostate Cancer
|
5R01CA208254-02
|
$481,793
|
SWEENEY, CHRISTOPHER
|
DANA-FARBER CANCER INST
|
|
Anatomic Pathology Residency Program
|
ZIE BC 011384
|
$1,094,457
|
Barr, Frederic
|
CCR (NCI)
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
3R41CA200161-01A1S2
|
$50,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
Antigen-specific T-cell Activation, Application to Vaccines for Cancer and AID
|
ZIA SC 004020
|
$2,592,300
|
Berzofsky, Jay
|
CCR (NCI)
|
|
Antigen-specific T-cell Activation, Application to Vaccines for Cancer and AID
|
ZIA SC 004020
|
$2,592,300
|
Berzofsky, Jay
|
CCR (NCI)
|
|
Antiviral Mechanism of IFITM Proteins during HIV and Other Retrovirus Infections
|
ZIA BC 011779
|
$206,630
|
Compton, Alex
|
CCR (NCI)
|
|
Area B: Precise DCE-MRI Assessment of Brain Tumors
|
1R33CA225400-01
|
$1,561,994
|
NAYAK, KRISHNA
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S1
|
$118,333
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S2
|
$118,875
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S3
|
$122,250
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S4
|
$250,002
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-11
|
$3,253,119
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Biological Activity of Ras Oncogenes
|
5R01CA042978-31
|
$349,678
|
DER, CHANNING
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Biological characterization of matched primary colorectal carcinomas & metastases
|
5K08CA175150-05
|
$178,740
|
VAKIANI, EFSEVIA
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Biomaterial Mimicry of Dynamic Matrix Stiffening During Tumor Progression
|
5R01CA206880-02
|
$373,033
|
ENGLER, ADAM
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Biomaterials for treatment of head and neck cancer
|
5R01CA173292-05
|
$284,554
|
FORREST, MARCUS
|
UNIVERSITY OF KANSAS LAWRENCE
|
|
Bone and Soft Tissue Tumor Etiology: Role and Function of TRE17/USP6
|
5R01CA168452-05
|
$259,058
|
CHOU, MARGARET
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Brain Cancer Radio-Pathomics for Predicting Heterogeneous Cytology
|
1R01CA218144-01
|
$348,075
|
LAVIOLETTE, PETER
|
MEDICAL COLLEGE OF WISCONSIN
|
|
Breaking the Obesity-Cancer Link: New Targets and Strategies
|
5R35CA197627-03
|
$762,608
|
HURSTING, STEPHEN
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|